Loading company…
OxThera develops Oxabact, an oral therapy for Primary Hyperoxaluria, a rare kidney disease, from Stockholm, Sweden.
Founded in 2005 in Stockholm, Sweden, OxThera AB is a biopharmaceutical company spun out from Q-Med that develops treatments for rare kidney diseases, focusing on Primary Hyperoxaluria. Its core product, Oxabact, is an orally administered bimodal enteric biotherapy. The company raised EUR 32 million in November 2016, co-led by EQT Life Sciences and Ysios Capital Partners. The listed stage is Series B.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in